Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide plus neoadjuvant chemotherapy in HR-positive/HER2-negative breast cancer
ChiCTR2200061074Phase 2Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in breast cancer, sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Residual cancer burden 0–1 points ratio. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200061074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061074.